This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document is …

… Joel Lavine, MD, PhD has received compensation for providing consultations related to
NAFLD from Quark Pharmaceuticals and Synageva BioPharma, and received research support …

Background Nonalcoholic steatohepatitis is a common liver disease that can progress to
cirrhosis. Currently, there is no established treatment for this disease. Methods We randomly …

Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal …

Guidelines; 1 (3) guideline policies of the three societies approving this document; and (4) the
experience of the authors and independent reviewers with regards to NAFLD. Intended for …

OBJECTIVE. Fatty liver disease is diagnosed increasingly in children, but the prevalence
remains unknown. We sought to determine the prevalence of pediatric fatty liver as diagnosed …

Context Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
in US children and adolescents and can present with advanced fibrosis or nonalcoholic …

Aim: To determine whether supplemental oral vitamin E is effective in lowering serum
aminotransferase and alkaline phosphatase levels in children with nonalcoholic steatohepatitis (…

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common
in children and adolescents. However, standard histological criteria for pediatric NAFLD …

OBJECTIVES: To determine short-term outcome for children with acute liver failure (ALF) as
it relates to cause, clinical status, and patient demographics and to determine prognostic …